Matinas BioPharma Holdings MTNB
NYSE MTNB
$1.59 -0.11 (-6.47%)
As of: Oct 21, 2026 · 3:15 PM EDT

Matinas BioPharma Holdings (MTNB) Change in Receivables (2015 - 2017)

Updated

Matinas BioPharma Holdings' Change in Receivables was -$5.00 in Q3 2017.

Analysis

Matinas BioPharma Holdings (MTNB) Change in Receivables (2015 - 2017) Analysis & Trends

  • The Q3 2017 figure marks the lowest quarterly Change in Receivables since Q1 2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,137.48 Bn 1,106.07 Bn 19.71 Bn -
2 Johnson & Johnson 618.81 Bn 537.34 Bn 17.26 Bn 1.35 Bn
3 AbbVie 502.02 Bn 475.14 Bn 12.70 Bn 1.37 Bn
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn -
5 Novartis Ag 297.87 Bn 261.86 Bn 11.24 Bn -
6 Astrazeneca 260.90 Bn 234.58 Bn 12.86 Bn -
7 Amgen 236.67 Bn 192.07 Bn 7.24 Bn 1.09 Bn
8 Gilead Sciences 191.16 Bn 165.36 Bn 6.22 Bn 333.00 Mn
9 Pfizer 169.69 Bn 116.34 Bn 10.94 Bn -
10 Matinas BioPharma Holdings 679,055.62 -11.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 -5.00
Jun 30, 2015 29,748.00
Mar 31, 2015 -15,535.00
API Access

Matinas BioPharma Holdings Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=MTNB&period=max&api_key=YOUR_API_KEY